18 results
425
APGN
Apexigen Inc
11 Aug 23
Business combination disclosure
7:26am
) posters describing the PYX-106-101 and PYX-201-101 Phase 1 clinical trials were accepted for presentation at the Society for the Immunotherapy of Cancer
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that showed that patients with dedifferentiated liposarcoma (“LPS
425
EX-99.1
APGN
Apexigen Inc
24 May 23
Business combination disclosure
4:55pm
LPS: liposarcoma ASCO: American Society of Clinical Oncology FACT: flexible antibody conjugation technology PFS: progression free survival ADC
425
PYXS
Pyxis Oncology Inc
24 May 23
Business combination disclosure
7:05am
is anticipated to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in early June.
Prolonged durations of PR and SD
8-K
EX-99.1
APGN
Apexigen Inc
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
is anticipated to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in early June.
Prolonged durations of PR and SD achieved
424B3
gwmvqoy 7n
10 Apr 23
Prospectus supplement
4:03pm
424B3
k7j9bs5
10 Apr 23
Prospectus supplement
4:02pm
POS AM
472a5t24j0 4o4o
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
wpkzhobeiifq69ye
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
pp7x78qc1
9 Sep 22
Prospectus supplement
4:40pm
424B3
4ior2ky axx3
9 Sep 22
Prospectus supplement
4:38pm
8-K
EX-99.1
45aa12
1 Aug 22
Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
9:15am
425
svqya
3 Jun 22
Business combination disclosure
4:57pm
- Prev
- 1
- Next